News NICE will only fund Opdivo in PD-L1 lung cancer patients Pharma must apply for Cancer Drugs Funding in restricted population - NICE
News Some good news for BMS with Opdivo + natural killer cell com... But BMS dumps combination with Yervoy.
News Scotland's Opdivo decision sparks funding row Patients in Scotland will receive lung cancer drug, those in England will not.
News AZ pays Heptares $10m as cancer trial begins Phase 1 study of immuno-oncology drug candidate begins.
R&D BMS looks for cancer combos with Cormorant buy Bristol searching for new immuno-oncology combinations.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
